4basebio signs strategic collaboration, marketing agreement with Genezen on synthetic DNA for viral vectors

Reuters2026/08/26 06:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

4basebio signed a non-exclusive strategic collaboration and marketing agreement with viral vector CDMO Genezen.
Deal gives Genezen access to Research Use Only, high-quality, and GMP-grade hpDNA technology for development and clinical programs.
Parties will coordinate commercial activity, including joint sales efforts and technical presentations.
Cell-free, enzymatic DNA aims to remove microbial contamination risk and avoid antibiotic resistance genes in viral vector starting material.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BASEBIO plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608260200PR_NEWS_PRUKDSCX_0003) on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

4basebio signs strategic collaboration, marketing agreement with Genezen on synthetic DNA for viral vectors

You may also like

Crypto prices